{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T16:21:07Z","timestamp":1794673267805,"version":"4.9.1"},"reference-count":51,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,11,20]],"date-time":"2017-11-20T00:00:00Z","timestamp":1511136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Memorial Sloan Kettering Core Grant","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:p>Drug regulators around the world make decisions about drug approvability based on qualitative benefit\u2013risk analysis. In this work, a quantitative benefit\u2013risk analysis approach captures regulatory decision\u2010making about new drugs to treat multiple myeloma (MM). MM assessments have been based on endpoints such as time to progression (TTP), progression\u2010free survival (PFS), and objective response rate (ORR) which are different than benefit\u2013risk analysis based on overall survival (OS). Twenty\u2010three FDA decisions on MM drugs submitted to FDA between 2003 and 2016 were identified and analyzed. The benefits and risks were quantified relative to comparators (typically the control arm of the clinical trial) to estimate whether the median benefit\u2013risk was positive or negative. A sensitivity analysis was demonstrated using ixazomib to explore the magnitude of uncertainty. FDA approval decision outcomes were consistent and logical using this benefit\u2013risk framework.<\/jats:p>","DOI":"10.1002\/cpt.871","type":"journal-article","created":{"date-parts":[[2017,9,13]],"date-time":"2017-09-13T11:07:39Z","timestamp":1505300859000},"page":"67-76","source":"Crossref","is-referenced-by-count":14,"title":["A Benefit\u2013Risk Analysis Approach to Capture Regulatory Decision\u2010Making: Multiple Myeloma"],"prefix":"10.1111","volume":"103","author":[{"given":"G.K.","family":"Raju","sequence":"first","affiliation":[{"name":"Light Pharma, Inc., Massachusetts Institute of Technology Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Gurumurthi","sequence":"additional","affiliation":[{"name":"Light Pharma, Inc., Massachusetts Institute of Technology Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reuben","family":"Domike","sequence":"additional","affiliation":[{"name":"Light Pharma, Inc., Massachusetts Institute of Technology Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dickran","family":"Kazandjian","sequence":"additional","affiliation":[{"name":"U.S. Food and Drug Administration, Center for Drug Evaluation and Research National Cancer Institute Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gideon M.","family":"Blumenthal","sequence":"additional","affiliation":[{"name":"U.S. Food and Drug Administration, Center for Drug Evaluation and Research National Cancer Institute Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Farrell","sequence":"additional","affiliation":[{"name":"U.S. Food and Drug Administration, Center for Drug Evaluation and Research National Cancer Institute Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Pazdur","sequence":"additional","affiliation":[{"name":"U.S. Food and Drug Administration, Center for Drug Evaluation and Research National Cancer Institute Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Woodcock","sequence":"additional","affiliation":[{"name":"U.S. Food and Drug Administration, Center for Drug Evaluation and Research National Cancer Institute Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,11,20]]},"reference":[{"key":"e_1_2_6_1_1","volume-title":"Benefit\u2010Risk Framework","author":"Frey P","year":"2012"},{"key":"e_1_2_6_2_1","volume-title":"Structured Approach to Benefit\u2010Risk Assessment in Drug Regulatory Decision\u2010Making","author":"U.S. Food and Drug Administration","year":"2013"},{"key":"e_1_2_6_3_1","unstructured":"U.S. Department of Health and Human Services Centers for Disease Control and Prevention National Center for Health Statistics.Health United States 2010: With Special Feature on Death and Dying. Hyattsville MD;2011."},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.93"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.88"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.507"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.501"},{"key":"e_1_2_6_8_1","unstructured":"U.S. Department of Health and Human Services U.S. Food and Drug Administration.Expedited Programs for Serious Conditions \u2014 Drugs and Biologics. Washington DC;2013."},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-568915"},{"key":"e_1_2_6_10_1","unstructured":"American Cancer Society.Survival rates by stage for multiple myeloma. [Online].2016[cited 2016 Feb 16]. Available from: <http:\/\/www.cancer.org\/cancer\/multiplemyeloma\/detailedguide\/mulitiple\u2010myeloma\u2010survival\u2010rates>"},{"key":"e_1_2_6_11_1","unstructured":"U.S. Food and Drug Administration.Drug Approval Package; Empliciti (Elotuzumab): Company: Bristol\u2010Myers Squibb; Application No.: 761035Orig1s000; Approval Date; 11\/30\/2015. [Online].2016[cited 2016 Feb 16]. Available from: <http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/761035Orig1s000TOC.cfm>"},{"key":"e_1_2_6_12_1","unstructured":"U.S. Food and Drug Administration.Drug Approval Package; Velcade (Bortezomib) Injection; Company: Millenium Pharmaceuticals; Application No.: 021602; Approval Date: 5\/13\/2003. [Online].2003[cited 2015 June 9]. Available from: <http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2003\/21602_Velcade.cfm>"},{"key":"e_1_2_6_13_1","unstructured":"U.S. Food and Drug Administration.Drug Approval Package; Revlimid (Lenalidomide) Capsules; Company: Celgene; Application No.: 021880\/S\u2010001; Approval Date: 06\/29\/2006. [Online].2006[cited 2015 June 25]. Available from: <http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm>?fuseaction=Search.Label_ApprovalHistory#apphist>"},{"key":"e_1_2_6_14_1","unstructured":"U.S. Food and Drug Administration.Drug Approval Package; Thalomid (Thalidomide) Capsules; Company: Celgene; Application No.: 021430; Approval Date: 05\/25\/2006. [Online].2008[cited 2015 June 23]. Available from: <http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2006\/021430s000TOC.cfm>"},{"key":"e_1_2_6_15_1","unstructured":"U.S. Food and Drug Administration.Drug Approval Package; Pomalyst (Pomalidomide) Capsules; Company: Celgene Corporation; Application No.: 0204026; Approval Date: 02\/08\/2013. [Online].2013[cited 2015 June 23]. Available from: <http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/204026Orig1s000TOC.cfm>"},{"key":"e_1_2_6_16_1","first-page":"10","article-title":"United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy","volume":"12","author":"Kane R.C.","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_6_17_1","unstructured":"U.S. Food and Drug Administration.Drug Approval Package; Kyprolis (Carfilzomib) for Injection; Company: Onyx Pharmaceuticals; Application No.: 0202714; Approval Date: 07\/20\/2012. [Online].2012[cited 2015 June 23]. Available from: <http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/202714Orig1s000TOC.cfm>"},{"key":"e_1_2_6_18_1","unstructured":"U.S. Food and Drug Administration.Summary Minutes of the Oncologic Drug Advistory Comittee Meeting. [Online].2014[cited 2016 10 13]. Available from: <http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/OncologicDrugsAdvisoryCommittee\/UCM430826.pdf>"},{"key":"e_1_2_6_19_1","unstructured":"U.S. Food and Drug Administration.Drug Approval Package; Darzalex Daratumumab injection; Company: Janssen Biotech; Application No.: 761036; Approval Date: 11\/16\/2015. [Online]. [cited2016October 22]. Available from: <http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/761036Orig1s000TOC.cfm>"},{"key":"e_1_2_6_20_1","unstructured":"U.S. Food and Drug Administration.Drug Approval Package; Farydak (Panobinostat) Capsules; Company: Novartis Pharmaceuticals; Application No.: 0205353; Approval Date: 02\/13\/2015. [Online].2015[cited 2015 June 25]. Available from: <http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/205353Orig1s000TOC.cfm>"},{"key":"e_1_2_6_21_1","unstructured":"European Medicines Agency.Pomalidomide Celgene: International non\u2010proprietary name: pomalidomide. [Online].2013[cited 2016 Dec 20]. Available from: <www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2010_Public\u2010assessment_report\/human\/002682\/WC500147721.pdf>"},{"key":"e_1_2_6_22_1","unstructured":"European Medicines Agency.Assessment Report. [Online].2015[cited 2016 Dec 20]. Available from: <www.ema.europa\/edu\/docs\/en_GB\/document_library\/EPAR_\u2010_Assessment_Report_\u2010_Variation\/human\/000717\/WC500184943.pdf>"},{"key":"e_1_2_6_23_1","unstructured":"NIH U.S. National Libary of Science.DailyMed. [Online].2016[cited 2016 Dec 20]. Available from: <https:\/\/dailymed.nlm.nih.gov\/dailymed\/druginfo.cfm>?setid=2b25ef01\u20105c9e\u201011e1\u2010b86c\u20100800200c9a66>"},{"key":"e_1_2_6_24_1","unstructured":"NIH US National Library of Medicine.Label: Revlimid\u2010lenalidomide capsule. [Online]. Jan [cited Dec 202016]. Available from: <https:\/\/dailymed.nlm.nih.gov\/dailymed\/druginfo.cfm>?setid=5fa97bf5\u201028a2\u201048f1\u20108955\u2010f56012d296be>"},{"key":"e_1_2_6_25_1","unstructured":"NIH US National Library of Medicine.DailyMed. [Online]. March [cited Dec 202016]. Available from: <https:\/\/dailymed.nlm.nih.gov\/dailymed\/druginfo.cfm>?setid=21d9c619\u20107e94\u201049e2\u2010ac41\u201031e9ea96554a>"},{"key":"e_1_2_6_26_1","unstructured":"NIH US National Library of Science.DailyMed. [Online].2015[cited 2016 Dec 20]. Available from: <https:\/\/dailymed.nlm.nih.gov\/dailymed\/druginfo.cfm>?setid=2eda833b\u20101357\u20104ed4\u2010a093\u2010194524fcb061>"},{"key":"e_1_2_6_27_1","unstructured":"US National Institutes of Health.ClinicalTrials.gov. [Online].2015[cited 2016 Dec 20]. Available from: <https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00424047?term=NCT00424047&rank=1>"},{"key":"e_1_2_6_28_1","unstructured":"US National Institutes of Health.ClinicalTrials.gov. [Online].2009[cited 2016 Dec 20]. Available from: <https;\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00056160?term=NCT00056160&RANK=1>"},{"key":"e_1_2_6_29_1","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos M.","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"e_1_2_6_30_1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.2007.14.1853","article-title":"Multicenter, randomized, double\u2010blind, placebo\u2010controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma","volume":"26","author":"Rajkumar S.V.","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402551"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030288"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043445"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70380-2"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411321"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070596"},{"key":"e_1_2_6_37_1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski R.Z.","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607751"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00464-7"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"e_1_2_6_42_1","unstructured":"U.S. Food and Drug Administration.Guidance for industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. [Online].2007[cited 2016 October 24]. Available from: <http:\/\/www.fda.gov\/downloads\/Drugs\/.\/Guidances\/ucm071590.pdf>"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp0911494"},{"key":"e_1_2_6_44_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/djv216","article-title":"The imperative for a new approach to toxicity analysis in oncology clinical trials","volume":"107","author":"Thanarajasingam G.","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.2219"},{"key":"e_1_2_6_46_1","unstructured":"U.S. Food and Drug Administration.Drug Approval Package; Ninlaro (ixazomib) capsules; Company; Millennium Pharmaceuticals; Application No.; 208462; Approval Date: 11\/20\/2015. [Online].2015[cited 2016 Feb 16]. Available from: <http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/208462Orig1s000TOC.cfm>"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129"},{"key":"e_1_2_6_48_1","first-page":"1","article-title":"Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta\u2010analysis","author":"Landgren O.","year":"2016","journal-title":"Bone Marrow Transpl."},{"key":"e_1_2_6_49_1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1056\/NEJMe1609835","article-title":"Progress in myeloma \u2014 a monoclonal breakthrough","volume":"375","author":"Rajkumar S.","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21268"},{"key":"e_1_2_6_51_1","article-title":"Association of minimal residue disease with superior survival outcomes in patients with multiple myeloma: a meta\u2010analysis","author":"Munshi N.","year":"2016","journal-title":"JAMA Oncol."}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt.871","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.871","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:33:00Z","timestamp":1699363980000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,20]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1002\/cpt.871"],"URL":"https:\/\/doi.org\/10.1002\/cpt.871","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,20]]}}}